US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist
  • 1.020
  • -0.030-2.86%
Close Jul 3 13:00 ET
  • 1.020
  • 0.0000.00%
Post 16:55 ET
260.67MMarket Cap-1404P/E (TTM)

Adaptimmune Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
(Q2)Jun 30, 2022
Total revenue
-88.07%5.68M
122.05%60.28M
-97.91%231K
4.45%7.32M
-7.37%5.13M
1,231.50%47.6M
341.50%27.15M
678.26%11.03M
482.46%7.01M
78.93%5.54M
Operating revenue
-88.07%5.68M
122.05%60.28M
-97.91%231K
4.45%7.32M
-7.37%5.13M
1,231.50%47.6M
341.50%27.15M
678.26%11.03M
482.46%7.01M
78.93%5.54M
Cost of revenue
Gross profit
Operating expense
24.18%54.94M
5.03%198.32M
39.23%50.09M
7.91%53.95M
1.52%50.04M
-17.39%44.24M
12.13%188.82M
-18.76%35.97M
15.24%50M
16.23%49.29M
Selling and administrative expenses
5.55%19.73M
17.55%71.81M
30.63%16.88M
-3.87%16.16M
37.96%20.07M
11.25%18.69M
6.61%61.09M
-12.55%12.92M
10.82%16.82M
7.47%14.55M
-General and administrative expense
5.55%19.73M
17.55%71.81M
30.63%16.88M
-3.87%16.16M
37.96%20.07M
11.25%18.69M
6.61%61.09M
-12.55%12.92M
10.82%16.82M
7.47%14.55M
Research and development costs
37.81%35.21M
-0.95%126.51M
44.06%33.21M
13.88%37.79M
-13.74%29.97M
-30.49%25.55M
14.98%127.73M
-21.87%23.05M
17.62%33.18M
20.34%34.74M
Operating profit
-1,566.54%-49.26M
14.62%-138.04M
-99.86%-49.86M
-8.47%-46.63M
-2.64%-44.91M
106.72%3.36M
0.36%-161.67M
41.80%-24.95M
-1.92%-42.99M
-11.29%-43.75M
Net non-operating interest income expense
98.96%1.35M
286.77%5.96M
205.16%1.6M
563.27%2.15M
332.21%1.54M
100.00%676K
40.82%1.54M
192.18%523K
44.00%324K
34.21%357K
Non-operating interest income
98.96%1.35M
286.77%5.96M
205.16%1.6M
563.27%2.15M
332.21%1.54M
100.00%676K
40.82%1.54M
192.18%523K
44.00%324K
34.21%357K
Other net income (expense)
97.43%-61K
789.69%19.54M
91.84%-313K
-126.16%-430K
3,558.93%22.66M
-19,883.33%-2.37M
-173.55%-2.83M
-195.00%-3.83M
793.67%1.64M
-1,312.96%-655K
Special income (charges)
--0
985.76%20.35M
--0
---106K
--22.16M
---1.7M
---2.3M
---2.3M
--0
--0
-Less：Restructuring and merger&acquisition
--0
-985.76%-20.35M
--0
--106K
---22.16M
--1.7M
--2.3M
--2.3M
--0
--0
Other non- operating income (expenses)
90.91%-61K
-50.56%-807K
79.64%-313K
-119.71%-324K
176.49%501K
-5,691.67%-671K
-113.91%-536K
-138.08%-1.54M
793.67%1.64M
-1,312.96%-655K
Income before tax
-2,988.44%-47.98M
30.94%-112.54M
-71.90%-48.57M
-9.49%-44.91M
52.99%-20.71M
103.35%1.66M
-3.60%-162.96M
26.89%-28.26M
2.78%-41.02M
-12.97%-44.05M
Income tax
-15.84%526K
-46.50%1.34M
-166.00%-656K
72.18%687K
44.68%680K
-1.42%625K
215.68%2.5M
375.60%994K
91.83%399K
518.42%470K
Net income
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
2.31%-41.42M
-13.96%-44.52M
Net income continuous Operations
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
2.31%-41.42M
-13.96%-44.52M
Minority interest income
Net income attributable to the parent company
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
2.31%-41.42M
-13.96%-44.52M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
2.31%-41.42M
-13.96%-44.52M
Basic earnings per share
-2,970.81%-0.18
47.06%-0.54
0.00%-0.18
25.00%-0.18
60.00%-0.12
102.09%0.0063
0.00%-1.02
25.00%-0.18
20.00%-0.24
-25.00%-0.3
Diluted earnings per share
-2,996.68%-0.18
47.06%-0.54
0.00%-0.18
25.00%-0.18
60.00%-0.12
102.07%0.0062
0.00%-1.02
25.00%-0.18
20.00%-0.24
-25.00%-0.3
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022(Q2)Jun 30, 2022
Total revenue -88.07%5.68M122.05%60.28M-97.91%231K4.45%7.32M-7.37%5.13M1,231.50%47.6M341.50%27.15M678.26%11.03M482.46%7.01M78.93%5.54M
Operating revenue -88.07%5.68M122.05%60.28M-97.91%231K4.45%7.32M-7.37%5.13M1,231.50%47.6M341.50%27.15M678.26%11.03M482.46%7.01M78.93%5.54M
Cost of revenue
Gross profit
Operating expense 24.18%54.94M5.03%198.32M39.23%50.09M7.91%53.95M1.52%50.04M-17.39%44.24M12.13%188.82M-18.76%35.97M15.24%50M16.23%49.29M
Selling and administrative expenses 5.55%19.73M17.55%71.81M30.63%16.88M-3.87%16.16M37.96%20.07M11.25%18.69M6.61%61.09M-12.55%12.92M10.82%16.82M7.47%14.55M
-General and administrative expense 5.55%19.73M17.55%71.81M30.63%16.88M-3.87%16.16M37.96%20.07M11.25%18.69M6.61%61.09M-12.55%12.92M10.82%16.82M7.47%14.55M
Research and development costs 37.81%35.21M-0.95%126.51M44.06%33.21M13.88%37.79M-13.74%29.97M-30.49%25.55M14.98%127.73M-21.87%23.05M17.62%33.18M20.34%34.74M
Operating profit -1,566.54%-49.26M14.62%-138.04M-99.86%-49.86M-8.47%-46.63M-2.64%-44.91M106.72%3.36M0.36%-161.67M41.80%-24.95M-1.92%-42.99M-11.29%-43.75M
Net non-operating interest income expense 98.96%1.35M286.77%5.96M205.16%1.6M563.27%2.15M332.21%1.54M100.00%676K40.82%1.54M192.18%523K44.00%324K34.21%357K
Non-operating interest income 98.96%1.35M286.77%5.96M205.16%1.6M563.27%2.15M332.21%1.54M100.00%676K40.82%1.54M192.18%523K44.00%324K34.21%357K
Other net income (expense) 97.43%-61K789.69%19.54M91.84%-313K-126.16%-430K3,558.93%22.66M-19,883.33%-2.37M-173.55%-2.83M-195.00%-3.83M793.67%1.64M-1,312.96%-655K
Special income (charges) --0985.76%20.35M--0---106K--22.16M---1.7M---2.3M---2.3M--0--0
-Less：Restructuring and merger&acquisition --0-985.76%-20.35M--0--106K---22.16M--1.7M--2.3M--2.3M--0--0
Other non- operating income (expenses) 90.91%-61K-50.56%-807K79.64%-313K-119.71%-324K176.49%501K-5,691.67%-671K-113.91%-536K-138.08%-1.54M793.67%1.64M-1,312.96%-655K
Income before tax -2,988.44%-47.98M30.94%-112.54M-71.90%-48.57M-9.49%-44.91M52.99%-20.71M103.35%1.66M-3.60%-162.96M26.89%-28.26M2.78%-41.02M-12.97%-44.05M
Income tax -15.84%526K-46.50%1.34M-166.00%-656K72.18%687K44.68%680K-1.42%625K215.68%2.5M375.60%994K91.83%399K518.42%470K
Net income -4,781.76%-48.5M31.18%-113.87M-63.82%-47.92M-10.09%-45.6M51.96%-21.39M102.06%1.04M-4.66%-165.46M24.73%-29.25M2.31%-41.42M-13.96%-44.52M
Net income continuous Operations -4,781.76%-48.5M31.18%-113.87M-63.82%-47.92M-10.09%-45.6M51.96%-21.39M102.06%1.04M-4.66%-165.46M24.73%-29.25M2.31%-41.42M-13.96%-44.52M
Minority interest income
Net income attributable to the parent company -4,781.76%-48.5M31.18%-113.87M-63.82%-47.92M-10.09%-45.6M51.96%-21.39M102.06%1.04M-4.66%-165.46M24.73%-29.25M2.31%-41.42M-13.96%-44.52M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -4,781.76%-48.5M31.18%-113.87M-63.82%-47.92M-10.09%-45.6M51.96%-21.39M102.06%1.04M-4.66%-165.46M24.73%-29.25M2.31%-41.42M-13.96%-44.52M
Basic earnings per share -2,970.81%-0.1847.06%-0.540.00%-0.1825.00%-0.1860.00%-0.12102.09%0.00630.00%-1.0225.00%-0.1820.00%-0.24-25.00%-0.3
Diluted earnings per share -2,996.68%-0.1847.06%-0.540.00%-0.1825.00%-0.1860.00%-0.12102.07%0.00620.00%-1.0225.00%-0.1820.00%-0.24-25.00%-0.3
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions --Unqualified Opinion--------Unqualified Opinion------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg
Concept CAR-T Therapy
CAR-T Therapy
Intraday-0.34%